Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial - PubMed (original) (raw)
. 2013 Dec;11(12):1661-6.e1-3.
doi: 10.1016/j.cgh.2013.05.018. Epub 2013 May 23.
Affiliations
- PMID: 23707779
- DOI: 10.1016/j.cgh.2013.05.018
Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial
Lei Yu et al. Clin Gastroenterol Hepatol. 2013 Dec.
Abstract
Background & aims: Little is known about whether dietary cholesterol affects disease progression in patients with chronic hepatitis C virus infection.
Methods: We analyzed data from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial, which included patients with advanced fibrosis and compensated cirrhosis. Cholesterol intake was determined for 608 participants on the basis of responses to food frequency questionnaires, administered at baseline and 1.8 years later. We investigated whether cholesterol intake was associated with clinical progression (death, variceal bleeding, encephalopathy, ascites, peritonitis, Child-Turcotte-Pugh score ≥ 7, or hepatocellular carcinoma) or histologic progression of disease (an increase in Ishak fibrosis score of 2 or more points in a second liver biopsy compared with the first).
Results: After adjustments for age, sex, race, presence of cirrhosis, body mass index, treatment with peginterferon, lifetime alcohol consumption, smoking, health status, and coffee and macronutrient intake, each higher quartile of cholesterol intake was associated with a 46% increase in the risk of clinical or histologic progression (adjusted hazard ratio [AHR], 1.46; 95% confidence interval [CI], 1.13-1.87; P for the trend = .004). Compared with patients in the lowest quartile of cholesterol intake (32-152 mg/day), those in the 3rd (224-310 mg/day; AHR, 2.83; 95% CI, 1.45-5.51) and 4th quartiles (>310 mg/day; AHR, 2.74; 95% CI, 1.22-6.16) had significantly increased risk of disease progression.
Conclusions: On the basis of analysis of data from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial, higher dietary cholesterol intake is associated with higher risk of disease progression in HCV-infected patients with advanced fibrosis or compensated cirrhosis.
Keywords: AHR; BMI; CI; CTP; Child–Turcotte–Pugh; Cholesterol; Cirrhosis; Diet; FFQ; HALT-C; HCC; HCV; Hepatitis C; Hepatitis C Antiviral Long-term Treatment Against Cirrhosis; MTP; TLR; Toll-like receptor; adjusted hazard ratio; body mass index; confidence interval; food frequency questionnaire; hepatitis C virus; hepatocellular carcinoma; microsomal triglyceride transfer protein.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
- Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection.
Yu L, Morishima C, Ioannou GN. Yu L, et al. Br J Nutr. 2016 Jan 28;115(2):193-201. doi: 10.1017/S0007114515004158. Epub 2015 Nov 6. Br J Nutr. 2016. PMID: 26541123 - Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.
Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Veldt BJ, et al. Hepatology. 2008 Jun;47(6):1856-62. doi: 10.1002/hep.22251. Hepatology. 2008. PMID: 18506898 - Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P. Bruno S, et al. Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7. Am J Gastroenterol. 2009. PMID: 19352340 - Overview of Complications in Cirrhosis.
Premkumar M, Anand AC. Premkumar M, et al. J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14. J Clin Exp Hepatol. 2022. PMID: 35814522 Free PMC article. Review. - Hepatitis C virus: the burden of the disease.
Adler M, Goubau P, Nevens F, Van Vlierberghe H. Adler M, et al. Acta Gastroenterol Belg. 2002 Apr-Jun;65(2):83-6. Acta Gastroenterol Belg. 2002. PMID: 12148444 Review.
Cited by
- Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine.
Hermanson JB, Tolba SA, Chrisler EA, Leone VA. Hermanson JB, et al. J Nutr Biochem. 2024 Nov;133:109704. doi: 10.1016/j.jnutbio.2024.109704. Epub 2024 Jul 17. J Nutr Biochem. 2024. PMID: 39029595 Review. - Chronic Fibrosis and Its Progression to Cancer.
Yasuma T, Gabazza EC. Yasuma T, et al. Int J Mol Sci. 2022 Apr 1;23(7):3924. doi: 10.3390/ijms23073924. Int J Mol Sci. 2022. PMID: 35409286 Free PMC article. - The Impact of Hepatitis C Virus, Metabolic Disturbance, and Unhealthy Behavior on Chronic Kidney Disease: A Secondary Cross-Sectional Analysis.
Wang PC, Wu YF, Lin MS, Lin CL, Chang ML, Chang ST, Weng TC, Chen MY. Wang PC, et al. Int J Environ Res Public Health. 2022 Mar 17;19(6):3558. doi: 10.3390/ijerph19063558. Int J Environ Res Public Health. 2022. PMID: 35329244 Free PMC article. - Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies.
Jia F, Hu X, Kimura T, Tanaka N. Jia F, et al. Int J Mol Sci. 2021 Sep 24;22(19):10303. doi: 10.3390/ijms221910303. Int J Mol Sci. 2021. PMID: 34638640 Free PMC article. Review. - Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Horn CL, et al. Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24. Hepatol Commun. 2022. PMID: 34558856 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources